Avant Brands and IM Cannabis Corp. jointly announce the signing of an international trademark licensing agreement granting IMC the exclusive right to launch the BLKMKT brand in the Israeli medical cannabis market. The Licensing Agreement constitutes a significant milestone in the maturing and mutually beneficial relationship between the two cannabis companies in the Canadian and Israeli medical cannabis markets.
Under the terms of the License Agreement, a subsidiary of Avant will license the Company's premium-cannabis flagship BLKMKT brand to an Israeli subsidiary of IMC for use on IMC's medical cannabis product packaging. All such packaging will contain cannabis cultivated exclusively by Avant and sold to IMC affiliates. The integration of unique and exclusive varieties of the high-quality BLKMKT brand into the current IMC premium product portfolio will serve to bolster the cooperative and synergistic partnership forged between the two companies over the past two years. It will further strengthen IMC's business model in Israel that offers medical cannabis patients quality, ultra-premium brands, such as WAGNERS, IMC, and more.
The Licensing Agreement signals IMC's commitment to implementing a premium strategy and acts as another step to establish the Company's leadership of the ultra-premium segment in Israel. IMC and Avant have enjoyed tremendous success from their partnership so far, which combines Avant's top-of-the-line products and IMC's excellent go-to-market execution. Thanks to this growing partnership, ultra-premium-priced strains, such as Alien SinMint Cookies and Watermelon Zkittlez, sold out in record time.
"We are excited to strengthen our highly successful partnership with IMC," said Norton Singhavon, CEO of Avant Brands. "This agreement represents a major milestone with respect to expanding our products and brands in international markets."
"Medical cannabis patients in Israel are demanding the highest quality indoor cannabis products. By evolving our partnership with Avant, we continue to improve our supply chain and ability to provide ultra-premium, quality products to the Israeli medical cannabis market," Oren Shuster, CEO of IM Cannabis, commented.
Avant has made multiple shipments to Israel under the terms of a previously announced supply agreement with Focus Medical Herbs. In order to facilitate these exports, Avant's cultivation facilities must successfully complete rigorous audits in order to secure ICANN-G.A.P accreditation from the Israeli Institute of Quality & Control.
For more information:
Avant Brands 
www.avantbrands.ca